Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;10(2):99-106.
doi: 10.1007/s10238-009-0073-x. Epub 2009 Oct 14.

Structural changes in alpha1-adrenoceptor antagonist-treated human prostatic stroma

Tetsuya Imamura  1 , Kenichiro Ishii, Hideki Kanda, Shigeki Arase, Yuko Yoshio, Yasuhide Hori, Norihito Soga, Hideaki Kise, Kiminobu Arima, Yoshiki Sugimura
Affiliations

Structural changes in alpha1-adrenoceptor antagonist-treated human prostatic stroma

Tetsuya Imamura et al. Clin Exp Med. 2010 Jun.

Abstract

Alpha1-adrenoceptor antagonists (alpha1-blockers) are currently used as first-line drugs for the treatment of benign prostatic hyperplasia (BPH). However, cases of BPH are often encountered in which the efficacy of alpha1-blockers decreases and switching to surgical treatment is required. One factor responsible for this resistance includes structural changes in prostatic tissue architecture following repeated oral administration of alpha1-blockers. Forty patients suspected of having prostate cancer, but without evidence of malignancy on prostatic biopsy were divided into two groups: an untreated group (n = 17) and an oral alpha1-blocker-treated group (n = 23). Twenty-one patients exhibiting resistance to oral alpha1-blocker therapy who underwent surgery were assigned into the surgically treated group. Each tissue sample was subjected to Masson's trichrome staining to distinguish collagen fibers from smooth muscle constituting prostatic stroma. The mean collagen fiber share was 62.2 +/- 10.4% in the untreated group, 72.1 +/- 9.1% in the oral alpha1-blocker-treated group, and 72.2 +/- 15.7% in the surgically treated group. Focusing on cases exhibiting high-collagen fiber share (70% or more), the distribution in each of the two alpha1-blocker-treated groups (16 of the 23 cases from the oral alpha1-blocker-treated group and 10 of the 21 cases from the surgically treated group) differed significantly from that in the untreated group (2 of the 17 cases). Our findings suggest that the accumulation of collagen fibers in prostatic stroma could be one of the factors responsible for alpha1-blocker treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. World J Gastroenterol. 2007 Jun 14;13(22):3056-62 - PubMed
    1. Prostate. 2005 Dec 1;65(4):355-64 - PubMed
    1. Scand J Urol Nephrol. 2007;41(5):422-9 - PubMed
    1. Prostate. 1999 Feb 15;38(3):216-27 - PubMed
    1. J Urol. 1992 Apr;147(4):1167-70 - PubMed

Publication types

Substances

LinkOut - more resources